Clinical Trial Update: Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tabalumab delivered via auto-injector or prefilled syringe in rheumatoid arthritis was terminated, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Tabalumab (tabalumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Rheumatoid Arthritis | Phase 3 | Status: TERMINATED | Results posted: 2018-04-26